BHC — Bausch Health Companies Share Price
Last trade - 00:00- $3.18bn
- $25.56bn
- $8.76bn
- 62
- 97
- 85
- 95
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.17 | ||
| PEG Ratio (f) | 0.03 | ||
| EPS Growth (f) | 369.54% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 4.19 | ||
| Price to Sales | 0.36 | ||
| EV to EBITDA | 11.47 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.18% | ||
| Return on Equity | n/a | ||
| Operating Margin | 11.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 8,601 | 8,027 | 8,434 | 8,124 | 8,757 | 9,393.12 | 9,604.39 | 0.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +6.41 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Directors
- Joseph Papa CHM (65)
- Sam Will CFO
- Thomas Appio CEX (59)
- Joseph Gordon CEX (57)
- Robert Spurr CEX (52)
- Christina Ackermann EVP (56)
- Paul Herendeen EVP (65)
- Thomas Ross LED (70)
- Richard De Schutter IND (80)
- Brett Icahn IND (41)
- Argeris Karabelas IND (67)
- Sarah Kavanagh IND (64)
- Steven Miller IND (32)
- John Paulson IND (65)
- Robert Power IND (64)
- Russel Robertson IND (73)
- Andrew von Eschenbach IND (79)
- Amy Wechsler IND (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 9th, 2013
- Public Since
- September 20th, 1994
- No. of Shareholders
- 1,790
- No. of Employees
- 20,270
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 366,672,723
- Address
- 2150 Saint-Elzear Blvd W, LAVAL, H7L 4A8
- Web
- https://www.bauschhealth.com/
- Phone
- +1 5147446792
- Contact
- Laurie Little
- Auditors
- PricewaterhouseCoopers LLP
Latest News for BHC
Upcoming Events for BHC
Q1 2024 Bausch Health Companies Inc Earnings Call
Q1 2024 Bausch Health Companies Inc Earnings Release
Bausch Health Companies Inc Annual Shareholders Meeting
Bausch Health Companies Inc Annual Shareholders Meeting
Q2 2024 Bausch Health Companies Inc Earnings Release
Similar to BHC
Abbvie
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
Catalent
New York Stock Exchange
FAQ
As of Today at 19:03 UTC, shares in Bausch Health Companies are trading at $8.69. This share price information is delayed by 15 minutes.
Shares in Bausch Health Companies last closed at $8.69 and the price had moved by +13% over the past 365 days. In terms of relative price strength the Bausch Health Companies share price has underperformed the S&P500 Index by -5.96% over the past year.
The overall consensus recommendation for Bausch Health Companies is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Bausch Health Companies does not currently pay a dividend.
Bausch Health Companies does not currently pay a dividend.
Bausch Health Companies does not currently pay a dividend.
To buy shares in Bausch Health Companies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $8.69, shares in Bausch Health Companies had a market capitalisation of $3.18bn.
Here are the trading details for Bausch Health Companies:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BHC
Based on an overall assessment of its quality, value and momentum Bausch Health Companies is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bausch Health Companies is $10.33. That is 18.87% above the last closing price of $8.69.
Analysts covering Bausch Health Companies currently have a consensus Earnings Per Share (EPS) forecast of $3.93 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bausch Health Companies. Over the past six months, its share price has outperformed the S&P500 Index by +0.79%.
As of the last closing price of $8.69, shares in Bausch Health Companies were trading +4.71% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bausch Health Companies PE ratio based on its reported earnings over the past 12 months is 2.17. The shares last closed at $8.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bausch Health Companies' management team is headed by:
- Joseph Papa - CHM
- Sam Will - CFO
- Thomas Appio - CEX
- Joseph Gordon - CEX
- Robert Spurr - CEX
- Christina Ackermann - EVP
- Paul Herendeen - EVP
- Thomas Ross - LED
- Richard De Schutter - IND
- Brett Icahn - IND
- Argeris Karabelas - IND
- Sarah Kavanagh - IND
- Steven Miller - IND
- John Paulson - IND
- Robert Power - IND
- Russel Robertson - IND
- Andrew von Eschenbach - IND
- Amy Wechsler - IND